Table 2.
Characteristics of hematological malignancies and solid cancer.
| Hematological malignancies | Total (n=51) |
|---|---|
| Type of hematological malignancies | |
| Lymphoma/Chronic lymphocytic leukemia | 27 (52·9%) |
| Myeloma | 18 (35·3%) |
| Acute myeloid leukemia | 3 (5·9%) |
| Myeloproliferative disorders | 3 (5·9%) |
| Status prior to admission | |
| Diagnosis without treatment | 9 (18·0%) |
| Ongoing treatment | 20 (40·0%) |
| Treated with favourable response | 13 (26·0%) |
| Treated without favourable response | 8 (16·0%) |
| Haematopoietic stem cell transplantation (HSCT) | |
| None | 41 (80·4%) |
| Allogeneic HSCT | 1 (2·0%) |
| Autologous HSCT | 9 (17·6%) |
| Hematological maligancy treatment in the last 4 weeks | |
| No | 24 (47·1%) |
| Yes | 27 (52·9%) |
| Solid tumors | Total (n=54) |
| Solid tumor type | |
| Breast | 6 (11·1%) |
| Colorectal | 10 (18·5%) |
| Lung | 12 (22·2%) |
| Prostate | 9 (16·7%) |
| Digestive organs, non colorectal | 8 (14·8%) |
| Urinary tract | 2 (3·7%) |
| Female genital organs | 2 (3·7%) |
| Central nervous system | 1 (1·9%) |
| Skin | 2 (3·7%) |
| Endocrine system | 2 (3·7%) |
| Metastasis | 23 (43·4%) |
| Metastasis location | |
| Central nervous system | 6 (13·0%) |
| Ganglionnary | 12 (26·1%) |
| Lung | 18 (39·1%) |
| Pleural | 6 (13·0%) |
| Abdomen, non liver | 6 (13·0%) |
| Liver | 16 (34·8%) |
| Endocrine system | 6 (13·0%) |
| Others | 10 (21·7%) |
| Status prior to admission | |
| Diagnosis without treatment | 12 (22·2%) |
| Ongoing treatment | 25 (46·3%) |
| Treated with favourable response | 14 (25·9%) |
| Treated without favourable response | 3 (5·6%) |
| Solid tumor treatment in the last 4 weeks | |
| No | 27 (50·0%) |
| Yes | 27 (50·0%) |